Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for Episodic Migraine

Study Title
Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine
Teva Identifier
TV48125-CNS-30050 | 2015-004598-34
ClinicalTrials.gov Identifier
NCT02629861
Study Status
Completed
Trial Condition(s)
Migraine
Interventions
Drug: Fremanezumab | Drug: Placebo

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years to 70 Years
Trial Duration
March 23, 2016 - April 10, 2017
Phase
Phase 3

Study Type

Interventional